

Study supports potential for injectable 'chemical vaccine' for malaria using atovaquone

October 20 2023



Phenotype characterization in vitro of isogenic wild type (WT) and cytochrome b Y268S mutant P. falciparum. **a** Cumulative number of asexual parasites in continuous culture. Growth rate of wild type parasites (y = 0.35x + 9.3) was 1.4-fold greater than that of mutant (y = 0.21x + 7.9); *n* timepoints = 36, $R^2 >$ 0.99, data from one continuous experiment. **b** Atovaquone activity against WT or Y268S asexual erythrocytic parasites (EC₅₀ 0.68 nM or 9.0 µM, respectively) was obtained by assaying [³H]hypoxanthine incorporation as a function of



atovaquone concentration. Depicted are mean \pm SD of quadruplicate determinations from each of three biological replicate experiments (for each data point n = 12; some SD are too small to extend outside the symbols); $R^2 \ge$ 0.994. **c** Male gametocyte exflagellation, adjusted to 1.5% gametocytemia. *Bars*, median number of centers across four independent biological replicates (ranges 4 to 28 for WT, and 0 to 10 for mutant); n, the total number of fields examined; ****P

Citation: Study supports potential for injectable 'chemical vaccine' for malaria using atovaquone (2023, October 20) retrieved 9 May 2024 from https://medicalxpress.com/news/2023-10-potential-chemical-vaccine-malaria-atovaquone.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.